FDA RARELY WRITES “INEFFECTIVE CAPA” ON YOUR 483 — BUT YOUR OLD CAPA MAY BE WHAT DESTROYS YOUR INSPECTION

The most dangerous CAPA in your Quality System may be one everyone considers closed.

Your CAPA was investigated. Root cause was identified. Corrective actions were implemented. The effectiveness check passed. Quality approved it.

CLOSED — EFFECTIVE.

Then, two years later, an FDA Investigator finds essentially the same problem again.

What happens next?

In this former FDA Investigator’s examination of CAPA effectiveness, DeVaughn Edwards explains how a seemingly routine deviation can lead an Investigator backward through historical investigations, closed CAPAs, maintenance records, complaints, OOS/OOT investigations, APR/PQR data, previous FDA commitments and other Quality System records.

The real danger is not simply that FDA may determine that one CAPA was ineffective. The greater risk is that the recurrence causes FDA to question whether your organization can reliably identify root causes, implement meaningful corrective actions, detect recurrence and recognize when previous conclusions are no longer supported by the evidence.

Inside, you’ll learn how an Investigator may:

• Recognize recurrence even when events are recorded in different Quality systems
• Distinguish CAPA implementation from true verification of effectiveness
• Challenge “operator error” and retraining as sustainable corrective actions
• Use complaints, deviations, maintenance history and APR/PQR trends to test an old CAPA
• Expand from one questionable CAPA into a broader assessment of the CAPA system
• Evaluate CAPAs created in response to previous FDA inspections
• Determine whether an effectiveness check was actually capable of detecting failure
• 
  

The document also includes a practical inspection-readiness exercise: select significant CAPAs your company has already declared effective, ignore the effectiveness-check conclusion initially, and search the subsequent Quality System evidence to determine whether those CAPAs really worked.

The central question is one every pharmaceutical and biologics Quality organization should be able to answer:

If FDA ignored your CAPA effectiveness report and independently examined everything that happened afterward, would the evidence reach the same conclusion?

WHO SHOULD READ THIS?

Designed for pharmaceutical and biologics professionals responsible for Quality Assurance, Quality Systems, CAPA, investigations, manufacturing, laboratory operations, regulatory compliance, inspection readiness and senior Quality management.

This is not a generic CAPA training document. It is an examination of how a former FDA Investigator would follow the evidence during an actual inspection—and how an old CAPA can become evidence against the Quality System that declared it effective.

Written from the perspective of a former FDA Investigator with 14 years of FDA field experience and subsequent senior pharmaceutical Quality and Compliance leadership experience.

For organizational/professional use.